Tropisetron for postoperative nausea and vomiting in patients after gynaecological surgery.
In a double-blind study, we have compared the prophylactic antiemetic effect of tropisetron 5 mg (Navoban, a 5-HT3 receptor antagonist) with that of placebo, both given as a short i.v. infusion approximately 15 min before wound closure in patients undergoing gynaecological surgery. Perioperative anaesthetic care was standardized and patients were observed for at least 24 h after operation. The 35 patients given tropisetron and 34 given placebo treatment were well matched for characteristics. Vomiting occurred in 26% of tropisetron-treated patients, compared with 59% of placebo-treated patients (P = 0.006); 69% of tropisetron-treated patients suffered nausea, compared with 88% of placebo-treated patients (P = 0.05). In addition, patients judged the antiemetic treatment with tropisetron as more effective than the placebo treatment (visual analogue score 71 vs 51 mm (P = 0.003)).
Zomers
P J
PJ
Department of Anaesthesiology, Ziekenhuis de Honte, Terneuzen, The Netherlands.
Langenberg
C J
CJ
de Bruijn
K M
KM
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D005831:Genital Diseases, Female / Q000601:surgery; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D000077526:Tropisetron; D014839:Vomiting / Q000517:prevention & control*
D007211:Indoles; D012702:Serotonin Antagonists; D000077526:Tropisetron